GlassScriptPhysician profile
Brendan Collins
NPI 1720442411
$3,275.45
in general payments reported to CMS, 2019-2025
25 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $585 · 2024: $1,309 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.73 | 2023-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.81 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $240.23 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $224.64 | 2023-2025 | |
| Janssen Biotech, INC. | $217.30 | 2023-2025 | Simponi Aria, Stelara, Simponi |
| Lilly USA, LLC | $187.68 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $173.42 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $158.54 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $124.35 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $104.41 | 2024-2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $63.91 | 2023-2024 | Linzess |
| Celgene Corporation | $57.33 | 2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $56.11 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $55.67 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $43.84 | 2023-2024 | Ocaliva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.73 | 2024 | Dificid |
| Braintree Laboratories, INC. | $28.67 | 2024-2025 | Suflave, Sutab |
| Celltrion USA INC. | $23.05 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $20.28 | 2023 | Rebyota |
| Mimedx Group, INC. | $19.39 | 2024 | |
| Organon LLC | $18.82 | 2025 | Hadlima, Renflexis |
| Azurity Pharmaceuticals, INC. | $17.07 | 2025 | Suflave |
| Novo Nordisk INC | $16.74 | 2025 | Wegovy |
| Pacira Pharmaceuticals Incorporated | $15.88 | 2023 | Exparel |
| Biocon Biologics INC | $15.85 | 2025 | Yesintek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.